27
Jan
2026
27
Jan
2026
Polynucleotide injectables are now well established within regenerative aesthetic practice. Among available options, Plinest® and Newest® – both developed by Mastelli using PN-HPT (Polynucleotides High Purification Technology) – are widely used by medical practitioners seeking regenerative, non-volumising approaches to skin quality improvement.
For practitioners, the choice between Plinest® and Newest® is not about superiority, but about clinical indication, tissue behaviour, and protocol design.
Shared scientific foundation
Both Plinest® and Newest® are injectable medical devices based on highly purified polynucleotides. Their shared characteristics include:
As such, both treatments are positioned to support improvements in skin quality, texture, hydration dynamics, and overall dermal function rather than immediate structural change.
Key formulation difference
The primary distinction between the two products lies in their composition:
Plinest®
Newest®
This difference informs how each product is selected and positioned clinically.
Clinical selection in practice
Plinest® is commonly selected for:
Newest® is often chosen for:
Both products can be used across a broad age range, with selection guided by tissue assessment rather than chronological age.
Can Plinest® and Newest® be used together?
In practice, many clinicians incorporate both products within the same patient journey, applying them to different anatomical areas or at different stages of treatment.
Common strategies include:
This approach allows for tailored regenerative protocols without overlap or redundancy.
Safety, purity and tolerability
Plinest® and Newest® are manufactured by renowned pharmaceutical company Mastelli using a patented multi-step purification process.
The polynucleotides are sourced from trout bred in controlled freshwater environments. Mastelli’s production process is designed to be fully utilised with no waste, ensuring responsible use of raw materials.
During manufacture, the polynucleotides undergo repeated purification steps to remove residual proteins and other impurities. This results in highly purified, biocompatible polynucleotides suitable for use in delicate tissues and for repeat treatment protocols.
They have a favourable tolerability profile, with no adverse events reported when used in accordance with recommended protocols.
This focus on controlled sourcing and rigorous purification supports the consistent integration of Plinest® and Newest® into regenerative aesthetic practice.
Portfolio positioning for clinics
From a clinical and business perspective, Plinest® and Newest® serve complementary roles within a regenerative injectable offering.
Clinics introducing one or both products often value that they:
Rather than competing products, they function as adjacent tools within a regenerative framework.
The role of governance and training
While Mastelli develops and manufactures both formulations, distribution and clinical support in the UK and Ireland are provided exclusively by DermaFocus.
This ensures:
Such a structure supports safe, responsible adoption within medical practice.
Clinical takeaway
Plinest® and Newest® offer two distinct but complementary approaches to polynucleotide-based regeneration. Understanding their formulation differences allows practitioners to make informed choices based on tissue need, patient expectations, and protocol design.
For clinics developing or expanding a regenerative injectable portfolio, both products can play a valuable role when used thoughtfully and within appropriate clinical frameworks.
Read it? Loved it? Want to share it?
